-
Managing Risk in the Manufacture of Oncology Drugs
administered drugs Eloxatin (oxaliplatin), Taxotare (docetaxel) and Gemzar (gemcitabine) all of which will become generic by 2014. The global market for cytotoxic products is estimated by Datamonitor to peak in 2009. Quality Control | Managing Risk in the Manufacture of Oncology Drugs...
-
Managing Risk in the Manufacture of Oncology Drugs
of Oncology Drugs | Pharmaceutical Manufacturing. Digital Magazine: Read / Subscribe. RSS. Contact Us. Advertise. All. Articles. White Papers. Products. News. Member Login. Become a Member. Home. Topics. Aseptic Processing. Automation & Control. cGMPs Compliance. Contract Manufacturing. Drug Delivery...
-
Managing Risk in the Manufacture of Oncology Drugs
). This growth will be driven primarily by novel therapeutic biologics such as Avastin, Rituxan and Herceptin. The market for oncology-related clinical trials has also grown. Oncology represented 17.8%, or the largest share of clinical. Quality Control | Managing Risk in the Manufacture of Oncology Drugs...
-
Managing Risk in the Manufacture of Oncology Drugs
Web site. Managing Risk in the Manufacture of Oncology Drugs. Lee Karras, SVP of Operations, AAI Pharma, PharmaManufacturing.com. Containment, lyophilization and cleaning validation all must be top priorities when producing cytotoxic agents. Read more about. * Contract Manufacturing. * Fill & Finish...
-
Contract Research in China: A Catalyst for Pharmaceutical Industry Growth
and biotechnology industries relative to their huge population, he said. [They] will grow their share of pharmaceutical market value many times by 2030... CROs can help pharmaceutical companies develop drugs for marketing approval in China. Contract manufacturing was one of the first growth areas...
-
Contract Research Drives China's Pharma Sector
are endeavoring to meet international production standards for finished drugs. In 2004, Chinese CMOs generated $7.5 billion (RMB 60 billion) in domestic output, accounting for 13% of the country s gross pharmaceutical output not an. Contract Manufacturing | Contract Research Drives China's Pharma...
-
Contract Research in China: A Catalyst for Pharmaceutical Industry Growth
, and many are endeavoring to meet international production standards for finished drugs. In 2004, Chinese CMOs generated RMB 60 billion (US $7.5 billion) domestic output, [3] which accounted for 13% of the countrys gross pharmaceutical outputnot an insignificant figure considering contract...
-
Contract Research in China: A Catalyst for Pharmaceutical Industry Growth
, the company has completed preclinical studies for more than 400 state-level new drugs in China and has applied for 70 patents inside and outside China. Beijing KendleWit Medical Consulting Co., founded jointly in 1997 by Kendle International Inc. (U.S.) and the Beijing Wets Sci. & Tech. Co., is another...
-
Contract Research in China: A Catalyst for Pharmaceutical Industry Growth
an experimental animal service company. In August, the largest CRO (Sino-U.S. joint venture) in Beijing, Pharmaron (Beijing) Pharm. Tech, opened its new research lab (80,000 sq. meters) in the Beijing Economic and Technological Zone. This company receives $5 million in contract research work annually...
-
Auditing Contract Partners
and commercial manufacturing. DSM works in the areas of steriles, and orals and topicals, including dose form manufacturing, scheduled drugs, clinical manufacturing, fill/finish manufacturing, and lyophilization services. It also specializes in cytotoxics. www.dsm.com. Baxter BioPharma Solutions (Round...